New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
06:49 EDTJNJ, VRXJ&J among firms fined for price-fixing case in China, Bloomberg says
Johnson & Johnson (JNJ) and Valeant's (VRX) Bausch & Lomb were among the companies that were fined a combined $3M for price-fixing in the country’s contact lens and eye-glass market, according to Bloomberg, citing a statement from China’s National Development and Reform Commission on its website. Reference Link
News For JNJ;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
12:23 EDTVRXAllergan holder Paulson encourages deal with Shire, Reuters says
Subscribe for More Information
09:25 EDTVRXValeant says talks to Ackman 'frequently'
Subscribe for More Information
09:08 EDTVRXValeant says not planning to walk away from Allergan deal before Dec. 18
Subscribe for More Information
08:58 EDTVRXValeant says still willing to improve bid for Allergan
Valeant (VRX) said would raise Allergan (AGN) bid "when time is right." Says hopes Allergan shareholders see that Valeant's operating model does work and will continue to work. Says Valeant (VRX), Allergan have "unique" business overlap. Says company "should" own Allergan. Says interests with Pershing, Ackman "aligned" on Allergan.
08:37 EDTVRXValeant says 'completely focused' on Allergan acquisition
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:34 EDTVRXValeant says remains focused on completing Allergan transaction
Subscribe for More Information
07:32 EDTVRXValeant narrows FY14 revenue view to $8.1B-$8.3B from $8B-$8.3B
Subscribe for More Information
07:30 EDTVRXValeant CEO says 'can bid more than anyone' in financially sound Allergan deal
Pearson says "we cannot stop" another company from making a bid that does not make economic sense, but he believes Valeant (VRX) can "bid more than anyone" for Allergan (AGN) in a deal that makes financial sense. Pearson says he has met with doctor groups and that 95% of those he's spoken with support Valeant's bid for Allergan. Valeant CEO J. Michael Pearson spoke on CNBC.
07:28 EDTVRXValeant raises FY14 cash EPS to $8.22-8.32 from $7.90-$8.10
Subscribe for More Information
07:06 EDTVRXValeant raises FY15 outlook cash EPS $10.00 from $9.90
Subscribe for More Information
07:05 EDTVRXValeant raises Q4 cash EPS $2.45-$2.55 from $2.35-$2.45
Subscribe for More Information
07:03 EDTVRXValeant reports Q3 cash EPS $2.11, Q3 GAAP EPS 81c
Reports Q3 revenue revenue $2.1B; Reports Q3 total same store sales organic growth 19%. Bausch + Lomb organic growth was 12%. Q3 GAAP Operating Cash Flow $619 million, an increase of 207%; Adjusted Operating Cash Flow $771 million, an increase of 89%
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
09:47 EDTVRXValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:43 EDTVRXValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use